Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health Inc (NY: HIMS )

20.36 +1.53 (+8.13%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,245,000
Open 19.00
Bid (Size) 20.40 (4)
Ask (Size) 20.48 (5)
Prev. Close 18.83
Today's Range 18.70 - 20.59
52wk Range 6.210 - 25.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's... 
Via Benzinga
Exposures Product Safety
Smart Money Is Betting Big In HIMS Options
Via Benzinga

Performance

YTD
+111.20%
+111.20%
1 Month
+18.86%
+18.86%
3 Month
+14.13%
+14.13%
6 Month
+74.76%
+74.76%
1 Year
+214.20%
+214.20%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Could This Magnificent Pharma Stock 10x in the Next 5 Years?
Via The Motley Fool
How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals
From Hims & Hers
Via Business Wire
A Look Into Hims & Hers Health Inc's Price Over Earnings
Via Benzinga
How Is The Market Feeling About Hims & Hers Health?
Via Benzinga
This Is What Whales Are Betting On Hims & Hers Health
Via Benzinga
Top 3 Stocks Institutions Are Buying Right Now
Via MarketBeat
Hims & Hers Stock Dropped: Here's What You Need to Know
Via The Motley Fool
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Via Benzinga
Exposures Product Safety
Decoding 6 Analyst Evaluations For Hims & Hers Health
Via Benzinga
Hims & Hers names Dr. Jessica Shepherd as Chief Medical Officer of Hers
From Hims & Hers
Via Business Wire
In-Depth Examination Of 6 Analyst Recommendations For Hims & Hers Health
Via Benzinga
What Is Going On With Hims & Hers Stock?
Via The Motley Fool
Why Hims & Hers' Incredible Growth Will Continue
Via The Motley Fool
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
Via Investor's Business Daily
Exposures Product Safety
Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024
From Hims & Hers
Via Business Wire
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
Via Benzinga
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
Via Investor's Business Daily
Topics Lawsuit
Exposures Financial Legal Product Safety
Where Does Hims & Hers Stock Go From Here?
Via The Motley Fool
Exposures Product Safety
2 Incredibly Cheap Growth Stocks to Buy Right Now
Via The Motley Fool
2 No-Brainer Growth Stocks to Buy With $500 Right Now
Via The Motley Fool
Top 3 Stocks with Explosive Call Option Activity: What to Watch
Via MarketBeat
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.